Oragenics Inc (OGEN) - Total Assets
Based on the latest financial reports, Oragenics Inc (OGEN) holds total assets worth $7.49 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See OGEN book value for net asset value and shareholders' equity analysis.
Oragenics Inc - Total Assets Trend (2003–2025)
This chart illustrates how Oragenics Inc's total assets have evolved over time, based on quarterly financial data.
Oragenics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Oragenics Inc's total assets of $7.49 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 43.7% |
| Accounts Receivable | $53.08K | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2025)
This chart illustrates how Oragenics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Oragenics Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oragenics Inc's current assets represent 100.0% of total assets in 2025, an increase from 98.8% in 2003.
- Cash Position: Cash and equivalents constituted 43.7% of total assets in 2025, down from 98.2% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Oragenics Inc Competitors by Total Assets
Key competitors of Oragenics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Allakos Inc
NASDAQ:ALLK
|
USA | $59.55 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
|
USA | $460.00 Million |
|
Youcare Pharmaceutical Group Co. Ltd. A
SHG:688658
|
China | CN¥5.19 Billion |
|
MoonLake Immunotherapeutics
NASDAQ:MLTX
|
USA | $424.43 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
Oragenics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 133.42 | 1.04 | 16.38 |
| Quick Ratio | 133.42 | 1.04 | 16.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.43 Million | $137.69K | $32.55 Million |
Oragenics Inc - Advanced Valuation Insights
This section examines the relationship between Oragenics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.31 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | 583.7% |
| Total Assets | $10.07 Million |
| Market Capitalization | $2.42 Million USD |
Valuation Analysis
Below Book Valuation: The market values Oragenics Inc's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Oragenics Inc's assets grew by 583.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Oragenics Inc (2003–2025)
The table below shows the annual total assets of Oragenics Inc from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $10.07 Million | +583.71% |
| 2024-12-31 | $1.47 Million | -70.35% |
| 2023-12-31 | $4.97 Million | -66.35% |
| 2022-12-31 | $14.76 Million | -47.72% |
| 2021-12-31 | $28.23 Million | +51.13% |
| 2020-12-31 | $18.68 Million | -5.43% |
| 2019-12-31 | $19.75 Million | -10.42% |
| 2018-12-31 | $22.05 Million | +205.61% |
| 2017-12-31 | $7.21 Million | +67.43% |
| 2016-12-31 | $4.31 Million | -25.43% |
| 2015-12-31 | $5.78 Million | -48.09% |
| 2014-12-31 | $11.13 Million | -33.86% |
| 2013-12-31 | $16.83 Million | +60.48% |
| 2012-12-31 | $10.49 Million | +727.82% |
| 2011-12-31 | $1.27 Million | -26.67% |
| 2010-12-31 | $1.73 Million | -46.06% |
| 2009-12-31 | $3.20 Million | +100.92% |
| 2008-12-31 | $1.59 Million | +38.45% |
| 2007-12-31 | $1.15 Million | -28.30% |
| 2006-12-31 | $1.61 Million | -25.18% |
| 2005-12-31 | $2.15 Million | -51.94% |
| 2004-12-31 | $4.47 Million | +22.33% |
| 2003-12-31 | $3.65 Million | -- |
About Oragenics Inc
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation w… Read more